RxDoctor Payments DataLook up a doctor →

James Wheless, MD

Neurology with Special Qualifications in Child Neurology · Memphis, TNNPI 1659337855

Payments from drug & device makers

$2,534,895in general payments, 2019–2025

Across 1,890 payments — averaging $1341.21 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • SK Life Science, Inc.$440K
  • Neurelis, Inc.$254K
  • UCB, Inc.$219K
  • Eisai Inc.$216K
  • GW Research Limited$166K
  • UCB Biosciences Inc.$165K
  • plus $1.1M from 35 others
$111,641in research payments, 2019–2025

Across 89 payments — averaging $1254.40 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Neurelis, Inc.$53K
  • Neuropace, Inc.$42K
  • UCB, Inc.$17K

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
SK Life Science, Inc.240$439,878
Neurelis, Inc.202$253,695
UCB, Inc.407$219,480
Eisai Inc.166$215,844
GW Research Limited11$166,477
UCB Biosciences Inc.7$165,179
UCB SA29$162,129
Livanova USA, Inc.126$129,595
Jazz Pharmaceuticals Inc.153$127,353
Immedica Pharma US, Inc.48$111,756
Aquestive Therapeutics, Inc.41$105,232
H. Lundbeck A S22$76,103
Greenwich Biosciences, Inc.101$68,777
Zogenix Inc.37$47,692
Supernus Pharmaceuticals, Inc.50$45,205
Azurity Pharmaceuticals, Inc.16$36,587
Sunovion Pharmaceuticals Inc.75$34,851
Biocodex, Inc.57$34,557
Aucta Pharmaceuticals, Inc.9$15,500
Mallinckrodt Enterprises LLC10$13,868
Biomarin Pharmaceutical Inc.10$10,935
Shire North American Group Inc2$10,000
Radius Health, Inc.5$7,865
Neuropace, Inc.18$6,242
Lundbeck LLC4$5,844
Mallinckrodt Hospital Products Inc.2$5,700
Takeda Pharmaceuticals U.S.A., Inc.2$5,088
BTG International Inc.5$2,897
Upsher-smith Laboratories LLC16$2,615
Eisai CO., LTD.1$2,160
Nobelpharma America, LLC2$2,040
West Therapeutics Development, LLC2$1,750
Aprecia Pharmaceuticals, LLC2$1,400
Monteris Medical Corporation2$179
Spark Therapeutics, Inc.1$125
PTC Therapeutics, Inc.1$125
Acadia Pharmaceuticals Inc3$64
Catalyst Pharmaceuticals, Inc.2$51
TG Therapeutics, Inc.1$21
Otter Pharmaceuticals, LLC1$19
Pyros Pharmaceuticals, Inc.1$18

How this compares

$2,534,895 in reported general payments places this provider in the 95th percentile of 47 neurology with special qualifications in child neurology providers in Tennessee.

See all neurology with special qualifications in child neurology providers in Tennessee →

Medicare billing

Part B allowed, 2024
$3,645
Medicare patients
15
Services billed
31

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other neurology with special qualifications in child neurology in Memphis

See the full list for Tennessee →

Where these figures come from

Is this you, or does something look wrong? →